Mexico Bans P&U For Giving False Info
The Mexican Comptroller's Office has fined Pharmacia & Upjohn a total of27,450 pesos ($3,300) and banned the company from taking part in government contracts for six months to supply medicine. The decision was taken as a result of P&U allegedly giving false information in a tender put out by the Mexican Social Security Institute.
P&U did not complete a technical procedure in the bidding process, according to the company's director of medicine in Mexico, Jorge Yoma Medina, who added that the sanction had nothing to do with the efficacy or safety of the company's products. The sanction prohibits P&U from bidding to supply 92 of its key medicines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze